Title

Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis
Carotid Endarterectomy Versus Optimal Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis
  • Phase

    Phase 4
  • Study Type

    Interventional
  • Status

    Terminated
  • Study Participants

    400
The aim of this study is to determine whether optimal medical treatment can postpone carotid endarterectomy.
It is well known that risk of fatal and non-fatal stroke is increased in patients with significant carotid atherosclerosis. For asymptomatic patients, AHA guidelines recommend carotid endarterectomy (CEA) for stenosis 60% to 99%, if the risk of perioperative stroke or death is less than 3%.

Although clinical trial data support CEA in asymptomatic patients with carotid stenosis 60% to 79%, the AHA guidelines indicate that some physicians delay revascularization until there is greater than 80% stenosis in asymptomatic patients.

Our study is designed to determine whether optimal medical therapy alone reduces the risk of death and nonfatal stroke in patients with carotid artery stenosis as compared with CEA coupled with optimal medical therapy.
Study Started
Apr 30
2009
Primary Completion
May 31
2014
Study Completion
May 31
2014
Last Update
Oct 12
2015
Estimate

Procedure Carotid Endarterectomy

CEA involves a neck incision and physical removal of the plaque from the inside of the artery

Drug atorvastatin, aspirin, losartan, amlodipine

aspirin 100 mg/day, atorvastatin 10 mg/day, losartan 50 mg/day, amlodipine 5 mg/day

CEA Group Experimental

Patients will undergo carotid endarterectomy (CEA) and receive medical treatment including medical therapy with statins (at least 10 mg atorvastatin irrespective of the baseline cholesterol level), aspirin (100 mg daily) and antihypertensive therapy (at least 50 mg losartan and 5 mg amlodipine 75 mg daily irrespective of the baseline arterial pressure level). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations.

OMT Group Active Comparator

Patients will receive conservative therapy - optimal medical treatment (OMT) including statins (at least 10 mg atorvastatin irrespective of the baseline cholesterol level), aspirin (100 mg daily) and antihypertensive therapy (at least 50 mg losartan and 5 mg amlodipine 75 mg daily irrespective of the baseline arterial pressure level). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations.

Criteria

Inclusion Criteria:

Unilateral or bilateral carotid artery stenosis that was considered to be severe (carotid artery diameter reduction 70%-79% on ultrasound)
This stenosis had not caused any stroke, transient cerebral ischaemia, or other relevant neurological symptoms in the past 6 months
Both doctor and patient were substantially uncertain whether to choose immediate CEA, or deferral of any CEA until a more definite need for it was thought to have arisen
The patient had no known circumstance or condition likely to preclude long-term follow-up
Neurologist's explicit consent to potentially perform CEA

Exclusion Criteria:

Previous ipsilateral CEA
Expectation of poor surgical risk (e.g., because of recent acute myocardial infarction)
Some probable cardiac source of emboli (because the main stroke risk might then be from cardiac, not carotid, emboli)
Inability to provide informed consent
Underlying disease other than atherosclerosis (inflammatory or autoimmune disease)
Life expectancy < 6 months
Advanced dementia
Advanced renal failure (serum creatinine > 2.5 mg/dL)
Unstable severe cardiovascular comorbidities (e.g., unstable angina, heart failure)
Restenosis after prior CAS or CEA
Atrial fibrillation
Allergy or contraindications to study medications (statins, ASA, losartan, amlodipine)
No Results Posted